Please Wait a Moment
X

Articles

04Jan

FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma

04 Jan, 2022 | Return|

On December 28, 2021, the FDA updated the emergency use authorization  (EUA) for COVID-19 convalescent plasma.  The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment.  Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.

We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines. 

 

 

 

Related

October 20th Update on Ortho Conversion

The revised CTS algorithm associated with the Ortho platform is now available for review.  Clie...

Read More >

Sample submission during the national blood shortage

Through communications with our clients, CTS is aware of the current national blood shortage. We rea...

Read More >

Revised Client Forms

 Just a reminder that the revised client forms implement today! Don't forget to toss your o...

Read More >

Reminder- Check flights and cargo hours for the Thanksgiving Day Holiday

As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...

Read More >

CTS to Implement Licensed Babesia testing

In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols  ...

Read More >

Preparing for Hurricane Florence

As the US coast prepares for Hurricane Florence to make landfall, we have received importan...

Read More >